FDA Approves Spiriva Respimat For Maintenance Treatment of COPD

Boehringer Ingelheim Pharmaceuticals Inc. Sept. 25 said that the Food and Drug Administration has approved Spiriva Respimat (tiotropium bromide) inhalation spray.

The approval is for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients, the company said.

Boehringer Ingelheim said it anticipates Spiriva Respimat will be available in January 2015.

New Way to Deliver Medicine.

Spiriva Respimat provides a premeasured amount of medicine in a slow-moving mist that helps patients inhale the medicine, the company said. It was developed to actively deliver medication ...